Diagnosis and treatment of patients with malignant pleural effusion (MPE) is a serious problem for clinicians. The aim of the study were: to evaluate the diagnostic and therapeutic value of thoracoscopy and videothoracoscopy (VTS) and to determine the efficiency of using talc for the management of MPE. Material and methods. Between January 1996 and December 2006, thoracoscopy (VTS) was performed in 95 patients. A 4 g dose of talc was used for pleurodesis. Out of the 95 diagnostic procedures, malignancy was diagnosed in 94 (98.9%) patients. Patients were divided into two subgroups: subgroup A, patients (n=4) who died within first month, and subgroup B, patients (n=91) who lived more than one month. In subgroup A, complete remission (CR) was achieved in four (100%) patients until they died. In subgroup B, CR was achieved in 90 (98.9%) patients after one month, with relapse (R) occurring in 1 (1.1%) patient. After three months, CR was achieved in 86 (94.5%), partial remission (PR) in three (3.3%), and R in two (2.2%) patients. After six and nine months, CR was achieved in 85 (93.4%), PR in three (3.3%), and R in three (3.3%) patients. Postoperative complications, side effects after applying talc, and general performance were assessed. Difficulties in lung expansion requiring redrainage occurred in four (4.2%) patients. Fever appeared in 79 (83.2%) patients, while pain appeared in 90 (94.7%) patients. After treatment, the number of patients classified as I on the WHO scale increased from 36.8% to 74.7%, while the number of patients classified as III on the WHO scale decreased from 10.5% to 2.1%. Conclusions. Thoracoscopy (VTS) significantly improves diagnostic effectiveness in cases without cytological and histological diagnosis and is a method of treatment for MPE. Very good results were achieved after intrapleural administration of talc (CR occurred in 93.4% patients). The most common side effect of administering talc was pain.
Pleural effusion can appear in the course of different diseases. Lung cancer, breast cancer, and lymphoma account for approximately 70% of all MPE. In 7% of patients with diagnosed MPE, the primary focus is unknown. Diagnosis and treatment of patients with malignant pleural effusion is a serious problem for clinicians. Because effusion suggests generalization of the neoplastic disease, there is generally not an effective treatment, but in all cases, there may be an indication for palliative treatment to improve the quality of life (1) (2) (3) (4) (5) .
Thoracoscopy or videothoracoscopy is an effective diagnostic and therapeutic method in patients with diseases of the pleura. Thoracoscopy is performed as a diagnostic procedure when the definitive diagnosis is not established using non-invasive methods (1, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
The sensitivity of thoracoscopy in malignant and tuberculous pleural effusion is very high. Thoracoscopy allows differentiation between pleural mesothelioma and neoplastic metastases into the pleural cavity. Furthermore, in the case of mesothelioma, it allows exact determi-nation of the local advanced stage (8, 9) . In some cases, pathological lesions are not observed, and pleural effusion is caused by atelectasis or inflammation. In cases of pulmonary carcinoma, this changes the TNM classification and allows radical surgery to be performed (1) .
MATERIAL AND METHODS
Between January 1996 and December 2006, thoracoscopy or videothoracoscopy was performed in 95 patients with MPE. A 4 g dose of talc was used for pleurodesis.
This group consisted of patients requiring invasive diagnostic methods because of an unknown cause of pleural effusion, as well as patients with diagnosed neoplastic cells in a pleural effusion in which the kind of neoplasm or primary focus of the neoplasm was unknown or who were suspected to have another malignancy (tab. 1).
The presence of pleural fluid was detected by chest x-ray, computer tomography, or chest ultrasonography. An X-ray was obtained on each subject on admission, during the course of treatment, after treatment, and on followup visits or during next hospitalisations. It was sometimes difficult to detect the presence of pleural fluid, particularly after pleurodesis due to multiple pleural adhesions and lesions. Therefore, chest ultrasonography was performed in these cases. Thoracoscopy was performed under local or general anaesthesia, and VTS was performed only under general anaesthesia. After removal of the fluid from the pleural cavity, talc in the form of spray powder was spread on the surface of the pleurae. The use of a double-lumen tube is indicated during the endotracheal intubation, which allows ventilation of the one lung. The collapsed lung allows the investigation of the surface of the visceral and parietal pleurae and biopsy of the lesion.
Patients with histologically or cytologically confirmed neoplastic disease with MPE were qualified to take part in the study.
The general performance of patients was assessed using the WHO scale. Pulmonary and extrapulmonary symptoms were analyzed in the patients, and examination of the lung and other organs was performed. In addition, blood cell count determination and gasometry were performed.
The absence of pleural fluid was regarded as complete remission (CR), and the presence of a small amount of pleural fluid that did not produce symptoms and did not require thoracentesis was regarded as partial remission (PR). Pleural fluid re-accumulation was defined as an effusion that produced clinical symptoms and required thoracentesis (relapse-R).
RESULTS
The most common symptoms in this group of patients were dyspnoea (90.5%) and cough (55.8%) (tab. 2). Physical examination found removal of the alveolar murmur and dullness of sound in 100% cases. Cardiovascular disturbances were noticed in 33,7% of patients. Gasometry was performed in all patients three days before surgery. Comparison of the gasometry values was difficult, because gasometry was done at different times after thoracentesis. Values of the pH, pCO 2 Analysis of subgroup A showed that CR was achieved in 4 (100%) patients (tab. 4).
Analysis of subgroup B showed that the number of patients who needed further treatment was 91 (95.8%). After one month of management of MPE, CR was achieved in 90 (98.9%), and R occurred in 1 (1.1%) patient. After three months of management in this group, R occurred in one additional patient with CR after the first month. PR occurred in three patients with CR after the first month of treatment. After three months, in this group CR was achieved in 86 (94.5%), PR in three (3.3%), and R in two (2.2) patients. After six months of management, in this group R occurred in one patient with CR after three months. After six months, in this group CR was achieved in 85 (93.4%), PR in three (3.3%) and R in three (3.3%) patients. After nine months, R didn't occur in this group and CR was achieved in 98% cases. After 9 months, in this group CR was Malignant diseases were diagnosed in 94 (98.9%) of 95 thoracoscopies and VTSs that were performed. We did not determine the primary focus of the disease in one patient who underwent thoracoscopy, although malignancy was suspected. Lung cancer (adenocarcinoma) was diagnosed later from a biopsy specimen taken during bronchoscopy. In seven patients with diagnosed adenocarcinoma, despite additional examinations, the primary focus was not found. Out of the 95 thoracoscopies or VTS, the primary focus was established in 87 (91.6%) patients.
Efficacy of treatment for MPE
Due to the rapid progression of neoplastic disease and death of some patients within the first month of the treatment, the whole group was divided into two subgroups. Subgroup A was composed of the patients who died within the first month, and subgroup B included patients who lived more than one month. Complications of the operative procedure and pleural cavity drainage and side effects Difficulties in lung expansion requiring redrainage occurred in four (4.2%), air leakage in the drain in two (2.1%), leakage of fluid from the site of drain removal in two (2.1%) and wound infection in three (3.2%) patients.
The most common side effects after applying agents for chemical pleurodesis were fever or subfebrile body temperature appearing in 79 (83.2%), pain in 90 (94.7%), a pressure decrease of no more than 30 mm Hg in 3 (3.2%), and vomiting in five (5.3%) patients
Analysis of general condition
The number of patients classified as 1 on the WHO scale increased from 36.8% to 74.7%, the number of patients classified as 3 on the WHO scale decreased from 10.5% to 2.1% (tab. 6).
There were no patients classified as 0 or 1 on the WHO scale before treatment in subgroup A. An increase in the number of patients (75%) classified as 2 on the WHO scale after treatment was due to a short duration of improvement of the patients' general condition (tab. 7).
In patients from subgroup B, improvement of the general condition was observed. The number of patients classified as 1 on the WHO scale increased from 38.5% to 78%, while the number of patients classified as 3 on the WHO scale decreased from 7.7% to 2.2% and in the number classified as 2 on the WHO scale decreased from 52.7% to 18.7% (tab. 8).
Results of patient survival time
Average patient survival time after the first thoracentesis was 325 days. Average patient after treatment Asymptomatic 0 (0%) 0 (0%) Symptomatic, fully active 0 (0%) 0 (0%) Symptomatic, < 50% stay in bed a day 1 (25%) 3 (75%) Symptomatic, > 50% stay in bed a day 3 (75%) 0 (0%) Full time bed-care 0 (0%) 1 (25%)
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Diagnostic and therapeutic thoracoscopy (videothoracoscopy) in malignant pleural effusion survival time after ending of treatment of MPE was in this group was 274 days.
DISCUSSION
The most essential and important step in the diagnosis of MPE is thoracentesis and investigation of pleural fluid, including biochemical examination of fluid, bacteriological culture, tuberculosis examination, and cytological examination. The American Thoracic Society states that there is no absolute contraindication to performing thoracentesis (10) .
Patients with suspected neoplasms and negative cytological examination of pleural fluid undergo pleural biopsy or transthoracic needle biopsy, thoracoscopy, videothoracoscopy, and finally, diagnostic thoracotomy. The European Respiratory Society and American Thoracic Society recommend pleural biopsy in patients with suspected MPE using needle biopsy or thoracoscopy when the first thoracentesis has not given a positive cytological result (16) .
Thoracoscopy or VTS is a very sensitive method of diagnosing neoplastic disease, especially when the fluid is the first manifestation of the neoplasm. Morphological evaluation of tissue lesions with following cytochemical and immunological investigations allow diagnosis of the neoplastic disease (1, 6-11, 17, 18) . Boutin reported that out of 215 patients with pleural effusion who were diagnosed using thoracoscopy, malignancy was diagnosed in 150 cases. MPE was associated with metastases in 115 patients and mesothelioma was diagnosed in 35 patients. The primary focus of the disease was established in 131 (87%) using thoracoscopy (19) . Loddenkemper and Boutin reported that diagnosis of malignancy using thoracoscopy in 208 patients was established in 95% cases, while a positive cytological result from pleural fluid was achieved only in 62% (9) . In our study, 95 patients underwent thoracosco- py or VTS. Malignancy was diagnosed in 94 patients. In one patient, a biopsy specimen taken during thoracoscopy did not established the malignancy, but after three months adenocarcinoma was diagnosed from a biopsy specimen taken during bronchoscopy. Talc pleurodesis is a very effective method in the treatment of MPE. Talc may be introduced into the pleural cavity in powder form during the thoracoscopy or VTS. Thoracoscopy followed by talc introduction into the pleural cavity may be performed under local anaesthesia, but general anaesthesia is preferable. VTS is generally performed under general anaesthesia. We performed thoracoscopy under local anaesthesia in only a few cases. The optimal dose of talc has not yet established. Talc is introduced in doses from 1 to 14 g and mainly in doses of 5 g. In our Centre we introduced 4 g of talc into the pleural cavity. The data from the literature shows the possibility of achieving over 90% efficacy in the treatment of MPE (11, 15 ). Cardillo performed VTS followed by introduction of talc (5 g) into the pleural cavity, established a histological diagnosis in all patients, and achieved inhibition of increase in pleural fluid in 92.7% (558/602) (20) . Schultze et al. performed 119 VTS in 101 patients and administered talc (2-4 g) intrapleurally, achieving very good results in 68.8% and satisfactory results in 23.5%. Accumulation of the pleural fluid was stopped in 92.3%. There were no improvement of general condition, and early R occurred in 7.8% patients. Late R occurred in six (6.1%) patients (21) . In our study, talc was introduced into the pleural cavity during thoracoscopy. In subgroup B (n=91) CR was achieved after first month in 98.9%. After 9 months, CR was achieved in 94.5%, PR in 3.3%, and R in 3.3% (n=3). In subgroup A (n=4), R did not occur. Our results were very good, leading us to recommend talc pleurodesis in the treatment of patients with MPE. Complications after thoracoscopy occurred very rarely. We also performed an analysis of the side effects of the chemical agent. The most common side effect after using the chemical agent was fever or subfebrile temperature and pain. Fever and subfebrile temperature appeared in 83.2% and pain occurred in 94.7% patients associated with talc and thoracoscopy (VTS) procedure. There were no deaths after administration of talc intrapleurally. Other side effects occurred sporadically. CONCLUSIONS 1. Thoracoscopy (VTS) significantly improves diagnosis in cases without cytological and histological diagnosis and is the primary method of treatment for MPE. 2. Very good results were achieved after intrapleural administration of talc. 3. The most common side effect after administering talc was pain.
